We are live on ! Find out more
AQST icon

Aquestive Therapeutics

114 hedge funds and large institutions have $154M invested in Aquestive Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $605K

39% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

3% less funds holding

Funds holding: 117114 (-3)

3.79% less ownership

Funds ownership: 51.37%47.57% (-3.8%)

34% less capital invested

Capital invested by funds: $232M → $154M (-$78M)

Holders
114
Holders Change
-3
Holders Change %
-2.56%
% of All Funds
1.5%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
21
Increased
46
Reduced
33
Closed
22
Calls
$1.89M
Puts
$605K
Net Calls
+$1.28M
Net Calls Change
-$3.21M

AQST Hedge Fund Activity: Q4 2024 in Review

114 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2024, worth a combined $154M — down 34% from $232M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of AQST and 21 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 46 added.

The largest buyer was Goldman Sachs, adding an estimated $3.02M. The largest seller was VR Adviser, cutting an estimated $13.5M.

  • 114 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2024, down from 117 in Q3 2024.
  • Funds reported $154M of Aquestive Therapeutics stock for Q4 2024, down 34% quarter-over-quarter.
  • 21 funds opened new Aquestive Therapeutics positions in Q4 2024 and 22 closed out, a net change of -1 holder.
  • The largest Aquestive Therapeutics buyer in Q4 2024 was Goldman Sachs, an estimated $3.02M added.
  • The largest Aquestive Therapeutics seller in Q4 2024 was VR Adviser, an estimated $13.5M sold.

Based on aggregated 13F filings for Q4 2024.